Table 1 Demographics, baseline characteristics, and comorbiditiesa
From: The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Variable | Febuxostat 40 mg N = 115 | Febuxostat 80 mg N = 128 | Allopurinol 200/300 mg N = 131 |
|---|---|---|---|
Gender, n (%) | |||
Male | 104 (90.4) | 109 (85.2) | 108 (82.4) |
Female | 11 (9.6) | 19 (14.8) | 23 (17.6) |
Race, n (%) | |||
American Indian or Alaska Native | 1 (0.9) | 1 (0.8) | 0 |
Asian | 2 (1.7) | 4 (3.1) | 5 (3.8) |
Black or African American | 10 (8.7) | 16 (12.5) | 8 (6.1) |
Native Hawaiian or Other Pacific Islander | 1 (0.9) | 2 (1.6) | 0 |
White | 98 (85.2) | 103 (80.5) | 116 (88.5) |
Other | 3 (2.6) | 2 (1.6) | 2 (1.5) |
Ethnicity, n (%) | |||
Hispanic or Latino | 2 (1.7) | 3 (2.3) | 9 (6.9) |
Not Hispanic or Latino | 113 (98.3) | 125 (97.7) | 122 (93.1) |
Age (years) | |||
Mean ± SD | 70.8 ± 5.19 | 71.2 ± 5.22 | 70.1 ± 4.59 |
Range | 65-85 | 65-85 | 65-85 |
Body mass index (kg/m 2 ) | |||
Mean ± SD | 31.0 ± 5.47 | 30.7 ± 5.13 | 31.6 ± 5.60 |
Range | 20-48 | 16-49 | 22-48 |
Alcohol use, n (%) | |||
Non-/Ex-drinker | 42 (36.5) | 49 (38.3) | 53 (40.5) |
Drinker (1-14 drinks/week) | 73 (63.5) | 79 (61.7) | 78 (59.5) |
Serum urate (mg/dL) | |||
Mean ± SD | 9.4 ± 1.14 | 9.5 ± 1.17 | 9.3 ± 1.04 |
Range | 8-14 | 8-13 | 8-13 |
Years with gout | |||
Mean ± SD | 15.0 ± 11.3 | 14.8 ± 12.40 | 14.1 ± 12.44 |
Range | 0-53 | 0-50 | 0-48 |
Tophi present, n (%) | |||
No | 93 (80.9) | 104 (81.3) | 105 (80.2) |
Yes | 22 (19.1) | 24 (18.8) | 26 (19.8) |
Participated in a previous febuxostat study b, n (%) | |||
Yes | 18 (15.7) | 23 (18.0) | 21 (16.0) |
Prior urate lowering therapies, n (%) | |||
No | 31 (27.0) | 34 (26.6) | 44 (33.6) |
Yes (any) | 84 (73.0) | 94 (73.4) | 87 (66.4) |
Febuxostat | 17 (14.8) | 21 (16.4) | 18 (13.7) |
Allopurinol | 76 (66.1) | 85 (66.4) | 75 (57.3) |
Probenecid | 5 (4.3) | 6 (4.7) | 6 (4.6) |
Other | 4 (3.5) | 4 (3.1) | 3 (2.3) |
Renal Function c, n (%) | |||
Moderately Impaired | 67 (58.3) | 82 (64.1) | 80 (61.1) |
Mildly Impaired | 45 (39.1) | 44 (34.4) | 50 (38.2) |
Normal | 3 (2.6) | 2 (1.6) | 1 (0.8) |
Medical History, n (%) | |||
Any cardiovascular diseased | 102 (88.7) | 108 (84.4) | 116 (88.5) |
Hypertension | 98 (85.2) | 102 (79.7) | 108 (82.4) |
Coronary artery disease | 26 (22.6) | 28 (21.9) | 37 (28.2) |
Cardiac arrhythmia | 16 (13.9) | 28 (21.9) | 35 (26.7) |
Diabetes | 23 (20.0) | 35 (27.3) | 34 (26.0) |
Hypercholesterolemia | 15 (13.0) | 10 (7.8) | 17 (13.0) |
Hyperlipidemia | 66 (57.4) | 73 (57.0) | 84 (64.1) |
Use of low-dose aspirin (≤325 mg daily) | 48 (41.7) | 52 (40.6) | 49 (37.4) |